{"id":822165,"date":"2025-03-05T16:35:36","date_gmt":"2025-03-05T21:35:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/"},"modified":"2025-03-05T16:35:36","modified_gmt":"2025-03-05T21:35:36","slug":"theriva-biologics-to-participate-in-the-q1-investor-summit-virtual","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/","title":{"rendered":"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ROCKVILLE, Md., March  05, 2025  (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva\u2019s management team will participate in 1&#215;1 meetings.<\/p>\n<p align=\"justify\">\n        <strong>Q1 Investor Summit Virtual<\/strong><br \/>\n        <br \/>Format: Presentation<br \/>Presenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General Director<br \/>Presentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ET<br \/>Webcast: Click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w3BdiepASCMfUvff8uYG4vMOXD-1NQNjgv5p3oUDU-ohFt89tzvA5454obLmAx6puBzcjQlpx22zYPYbpflYv8wLl5n51loE4pl8jAq1cic=\" rel=\"nofollow\" target=\"_blank\">Here<\/a><\/p>\n<p>\n        <strong>About Theriva\u2122 Biologics,\u00a0Inc.<\/strong>\n      <\/p>\n<p>Theriva\u2122 Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient\u2019s immune system. The Company\u2019s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m7oOF-Jr8LmTnsd588PWKBSWGG3z-IY5ONKbvWxckflCPEux411XUH8SX-CCfVsiEGkabXd8nSLTj91Uey0x_9VzhVhAB7IyUHkki-HL6JA=\" rel=\"nofollow\" target=\"_blank\">www.therivabio.com<\/a>. \u00a0<\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\u00a0<br \/><strong>Investor Relations:<\/strong>\u00a0<br \/>Kevin Gardner<br \/>LifeSci Advisors, LLC\u00a0<br \/>kgardner@lifesciadvisors.com\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzI5NjdlYWItMGIwZi00MjQ1LWJkMzItY2NmYmNhODAyMGYxLTUwMDEwMTU4MQ==\/tiny\/Theriva-Biologics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva\u2019s management team will participate in 1&#215;1 meetings. Q1 Investor Summit Virtual Format: PresentationPresenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General DirectorPresentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ETWebcast: Click Here About Theriva\u2122 Biologics,\u00a0Inc. Theriva\u2122 Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-822165","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva\u2019s management team will participate in 1&#215;1 meetings. Q1 Investor Summit Virtual Format: PresentationPresenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General DirectorPresentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ETWebcast: Click Here About Theriva\u2122 Biologics,\u00a0Inc. Theriva\u2122 Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is &hellip; Continue reading &quot;Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-05T21:35:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual\",\"datePublished\":\"2025-03-05T21:35:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/\"},\"wordCount\":311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/\",\"name\":\"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==\",\"datePublished\":\"2025-03-05T21:35:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/","og_locale":"en_US","og_type":"article","og_title":"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual - Market Newsdesk","og_description":"ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) &#8212; Theriva\u2122 Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva\u2019s management team will participate in 1&#215;1 meetings. Q1 Investor Summit Virtual Format: PresentationPresenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General DirectorPresentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ETWebcast: Click Here About Theriva\u2122 Biologics,\u00a0Inc. Theriva\u2122 Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is &hellip; Continue reading \"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-05T21:35:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual","datePublished":"2025-03-05T21:35:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/"},"wordCount":311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/","name":"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==","datePublished":"2025-03-05T21:35:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4OTUzOSM2NzkyMjA1IzUwMDEwMTU4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theriva-biologics-to-participate-in-the-q1-investor-summit-virtual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Theriva\u2122 Biologics to Participate in the Q1 Investor Summit Virtual"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=822165"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=822165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=822165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=822165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}